Journal of Clinical Oncology, Vol 7, 993-1002, Copyright © 1989 by American Society of Clinical Oncology

ARTICLES

A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B

AP Chahinian, KJ Propert, JH Ware, B Zimmer, MC Perry, V Hirsh, A Skarin, S Kopel, JF Holland and RL Comis
Department of Neoplastic Diseases, Mount Sinai School of Medicine, New York.

The Cancer and Leukemia Group B (CALGB) conducted a prospective randomized trial to evaluate the role of warfarin and alternating chemotherapy in extensive small-cell lung cancer (SCCL). After stratification for sex and performance status, patients were randomly assigned to receive chemotherapy with methotrexate, doxorubicin (Adriamycin; Adria Laboratories, Columbus, OH), cyclophosphamide, and lomustine (CCNU) (MACC), or MACC plus warfarin (MACC + W), or mitomycin, etoposide, cisplatin, and hexamethylmelamine alternating with MACC (MEPH/MACC). Warfarin was given continuously to maintain a prothrombin time of one and one half to twice the control values. A total of 328 patients were enrolled, and 294 were evaluable. There was a statistically significant advantage in objective response rates (complete [CR] and partial responses [PR], respectively) for MACC + W (17% and 50%) as compared with MACC alone (8% and 43%) or MEPH/MACC (10% and 38%) (P = .012). Both failure-free survival (P = .054 Wilcoxon test) and overall survival (P = .098 Wilcoxon test) were higher on MACC + W (median, 6.6 months and 9.3 months, respectively), as compared with MACC (5.0 months and 7.9 months) and MEPH/MACC (5.0 months and 7.9 months). Toxicity was comparable among the three arms, except for increased hemorrhagic events on MACC + W, which were life-threatening in four patients (4%), and lethal in two others (2%). These data support the role of warfarin in the treatment of SCCL, but do not establish its mechanism of action. Warfarin deserves further studies in SCCL, particularly in patients with limited disease.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. W. Francis and N. Kuderer Effects of Anticoagulants on Survival for Patients with Cancer ASCO Educational Book, January 1, 2009; 2009(1): 326 - 330. [Abstract] [Full Text] [PDF]

				G. H. Lyman, A. A. Khorana, A. Falanga, D. Clarke-Pearson, C. Flowers, M. Jahanzeb, A. Kakkar, N. M. Kuderer, M. N. Levine, H. Liebman, et al. American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer J. Clin. Oncol., December 1, 2007; 25(34): 5490 - 5505. [Abstract] [Full Text] [PDF]

				K. Sideras, P. L. Schaefer, S. H. Okuno, J. A. Sloan, L. Kutteh, T. R. Fitch, S. R. Dakhil, R. Levitt, S. R. Alberts, R. F. Morton, et al. Low-Molecular-Weight Heparin in Patients With Advanced Cancer: A Phase 3 Clinical Trial Mayo Clin. Proc., June 1, 2006; 81(6): 758 - 767. [Abstract] [Full Text] [PDF]

				E. E. Vokes, M. C. Perry, H. L. Kindler, and M. R. Green The cancer and leukemia group B respiratory committee. Clin. Cancer Res., June 1, 2006; 12(11): 3581s - 3588s. [Abstract] [Full Text] [PDF]

				C. P.W. Klerk, S. M. Smorenburg, H.-M. Otten, A. W.A. Lensing, M. H. Prins, F. Piovella, P. Prandoni, M. M.E.M. Bos, D. J. Richel, G. van Tienhoven, et al. The Effect of Low Molecular Weight Heparin on Survival in Patients With Advanced Malignancy J. Clin. Oncol., April 1, 2005; 23(10): 2130 - 2135. [Abstract] [Full Text] [PDF]

				L. R. Zacharski, P. Prandoni, and M. Monreal Warfarin Versus Low-Molecular-Weight Heparin Therapy in Cancer Patients Oncologist, January 1, 2005; 10(1): 72 - 79. [Abstract] [Full Text] [PDF]

				H. Madari, D. Panda, L. Wilson, and R. S. Jacobs Dicoumarol: A Unique Microtubule Stabilizing Natural Product that Is Synergistic with Taxol Cancer Res., March 15, 2003; 63(6): 1214 - 1220. [Abstract] [Full Text] [PDF]

				T. T. Chen, J. P. Chute, E. Feigal, B. E. Johnson, and R. Simon A Model to Select Chemotherapy Regimens for Phase III Trials for Extensive-Stage Small-Cell Lung Cancer J Natl Cancer Inst, October 4, 2000; 92(19): 1601 - 1607. [Abstract] [Full Text] [PDF]

				A. Letai and D. J. Kuter Cancer, Coagulation, and Anticoagulation Oncologist, December 1, 1999; 4(6): 443 - 449. [Abstract] [Full Text]

				J. P. Chute, T. Chen, E. Feigal, R. Simon, and B. E. Johnson Twenty Years of Phase III Trials for Patients With Extensive-Stage Small-Cell Lung Cancer: Perceptible Progress J. Clin. Oncol., June 1, 1999; 17(6): 1794 - 1794. [Abstract] [Full Text] [PDF]

				M. Hejna, M. Raderer, and C. C. Zielinski Inhibition of Metastases by Anticoagulants J Natl Cancer Inst, January 6, 1999; 91(1): 22 - 36. [Abstract] [Full Text] [PDF]

				R. Scitz, N. Rappe, M. Wolf, H.-H. Heidtmann, M. Maasberg, A. Immel, M. Kraus, R. Egbring, R. Pfab, and K. Havemann Impaires Anticoagulant Activity of Protein C and Activation of Neutrophils in Extensive Lung Cancer Clinical and Applied Thrombosis/Hemostasis, March 1, 1995; 1(2): 131 - 134. [Abstract] [PDF]

				T. Urban, B. Lebeau, C. Chastang, P. Leclerc, M. J. Botto, and J. Sauvaget Superior Vena Cava Syndrome in Small-cell Lung Cancer Arch Intern Med, February 8, 1993; 153(3): 384 - 387. [Abstract] [PDF]

				ANTICOAGULATION AS A TREATMENT FOR SMALL-CELL LUNG CANCER Journal Watch (General), September 5, 1989; 1989(905): 2 - 2. [Full Text]